1. The role of positron emission tomography for non-small cell lung cancer 
Albert J. Chang, MD, PhD, Farrokh Dehdashti, MD, Jeffrey D. Bradley, MD 
Practical Radiation Oncology 
Volume 1, Issue 4, Pages (October 2011)
DOI: /j.prro
Copyright © 2011 American Society for Radiation Oncology Terms and Conditions

2. Figure 1
PET/CT alters radiation therapy volume delineation. In the left panel, CT demonstrated a right lower lobe spiculated mass. A PET/CT was subsequently performed demonstrating additional involvement in a subcarinal lymph node. PET/CT, positron emission tomography-computed tomography.
Practical Radiation Oncology 2011 1, DOI: ( /j.prro )
Copyright © 2011 American Society for Radiation Oncology Terms and Conditions

3. Figure 2
An improvement in tumor delineation and measurement of SUV is seen with gated FDG-PET in (A) compared to the corresponding ungated image in (B). The attenuation corrected SUV scale is shown to the right of each image. A plot of the SUV values with each plane of view is demonstrated in (C).40 FDG, 2-deoxy-2-(18F)fluoro-D-glucose; PET, positron emission tomography; SUV, standardized uptake values.
Practical Radiation Oncology 2011 1, DOI: ( /j.prro )
Copyright © 2011 American Society for Radiation Oncology Terms and Conditions

4. Figure 3
The transaxial CT (left), fused FLT-PET/CT (middle), and FLT-PET (right) images at the level of the lung cancer (arrow) demonstrate increased FLT uptake in the primary lung cancer. Physiological diffusely increased bone marrow active also is seen with FLT due to its high proliferative rate. This may limit detection of osseous metastasis. CT, computed tomography; FLT, 18F-3′-deoxy-3′-fluorothymidine; PET, positron emission tomography.
Practical Radiation Oncology 2011 1, DOI: ( /j.prro )
Copyright © 2011 American Society for Radiation Oncology Terms and Conditions